We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pharmaceutical Spending in Fee-for-Service Medicare: Looking Ahead to the Inflation Reduction Act.
- Authors
Gellad, Walid F.; Hernandez, Inmaculada
- Abstract
Editorial The prescription drug pricing provisions in the Inflation Reduction Act of 2022 constitute the most transformative reform to the Medicare prescription drug benefit since its inception almost 20 years ago. In 2020, government reports found that Medicare fee-for-service Part B drug spending increased 8.1% annually in the decade from 2006 to 2017, twice as fast as Part D drug spending.[12] Recently, MedPAC reported a 9.7% annual increase in Part B drug spending from 2009 to 2019.[13] While Part B coverage for drugs accounts for the minority of Medicare drug spending, the increasing trend is a marker of what is to come. However, these spending estimates cannot capture inpatient drugs (eg, expensive chimeric antigen T-cell therapies), meaning even the 27% figure is an underestimate of drug spending as a proportion of total Medicare spending among these Part D-enrolled beneficiaries.
- Subjects
UNITED States; FEE for service (Medical fees); MEDICAL care costs; ECONOMICS; DRUGS; MEDICARE
- Publication
JAMA: Journal of the American Medical Association, 2022, Vol 328, Issue 15, p1502
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.2022.18624